Orouracil (5-FU), doxorubicin, cyclophosphamide ?FAC) lead to survival advantage when compared
Orouracil (5-FU), doxorubicin, cyclophosphamide ?FAC) result in survival advantage when in comparison with the cyclophosphamide-methotrexate-5FU combination (CMF) with improvement in annual odds of recurrence and death by 11 and 12…